 |
        |
Seth Rudnick, M.D.Chairman of the Board Dr. Rudnick joined the ORTHOCON® Board of Directors in 2006 and represents Canaan Partners’ investment in the company. He currently is a Venture Partner to the life sciences venture capital investment team at Canaan Partners. Dr. Rudnick’s comprehensive experience bringing new medicines to fruition provides invaluable perspective to ORTHOCON. Prior to Canaan, Dr. Rudnick led many drug discovery and development projects, gaining deep operational experience in the pharmaceutical and biotech industries. He served as CEO and Chairman of CytoTherapeutics (CTII), a company developing stem cell-based therapies to combat chronic diseases, and also helped start and headed R&D for Ortho Biotech, a division of Johnson & Johnson that provides life-improving products to individuals with chronic illnesses. At Ortho Biotech, Dr. Rudnick was instrumental in creating a portfolio of products that still provide significant Johnson & Johnson revenue today. Dr. Rudnick began his career at Schering-Plough, a global science-based healthcare company, leading clinical trials, and also directed pharmaceutical development efforts at Biogen. Dr. Rudnick was a Yale Fellow in medical oncology where he was a Robert Wood Johnson Scholar. He received his medical training at Washington University Barnes Hospital. He earned his medical degree at the University of Virginia and holds a BA in history from the University of Pennsylvania. In 2006, Dr. Rudnick was named to the Midas List, a prominent venture capital ranking of the best dealmakers in technology and life science. He is currently a Clinical Professor of Medicine at University of North Carolina, Chapel Hill, teaching and advising faculty members on biotechnology issues. Return to Leadership |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
ORTHOCON® Names David J. Hart Vice President of Business Operations
March 15, 2012 - Click to Download Canaan Partners Closes $600 Million Fund, Canaan IX January 9, 2012 - Click to Read More |
||
|
||||||
